Literature DB >> 8636816

Natural history of Alström syndrome in early childhood: onset with dilated cardiomyopathy.

J L Michaud1, E Héon, F Guilbert, J Weill, B Puech, L Benson, J F Smallhorn, C T Shuman, J R Buncic, A V Levin, R Weksberg, G M Brevière.   

Abstract

Alström syndrome is an autosomal recessive disorder characterized by cone-rod dystrophy, obesity, hearing impairment, and diabetes caused by insulin resistance. By reviewing the charts of eight patients followed for periods of 2 to 22 years, we established the natural history of this syndrome during childhood. Five patients, in four families, were seen between the ages of 3 weeks and 4 months with a dilated cardiomyopathy, a previously unrecognized feature of the syndrome. Photophobia and nystagmus were first documented in the eight patients between the ages of 5 months and 15 months. In all patients, electroretinography initially showed a severe cone impairment with mild (2/8) or no (6/8) rod involvement. Electroretinograms, obtained again at ages 9 to 22 years for four patients, revealed extinguished rod-and-cone responses. Obesity developed during childhood in seven patients, in at least three of them before age 2 years. Hearing impairment (5/8) and diabetes/glucose intolerance (4/8) were diagnosed at the end of the first decade or during the second decade. This constellation of features should facilitate early diagnosis of the syndrome.

Entities:  

Mesh:

Year:  1996        PMID: 8636816     DOI: 10.1016/s0022-3476(96)70394-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

1.  Cohen syndrome - a rare genetic cause of hypotonia in children.

Authors:  Magdalena Budisteanu; Diana Barca; Sorina Mihaela Chirieac; Sanda Magureanu
Journal:  Maedica (Buchar)       Date:  2010-01

2.  Diagnostic criteria, clinical characteristics, and natural history of Cohen syndrome.

Authors:  K E Chandler; A Kidd; L Al-Gazali; J Kolehmainen; A-E Lehesjoki; G C M Black; J Clayton-Smith
Journal:  J Med Genet       Date:  2003-04       Impact factor: 6.318

3.  Alms1-disrupted mice recapitulate human Alström syndrome.

Authors:  G B Collin; E Cyr; R Bronson; J D Marshall; E J Gifford; W Hicks; S A Murray; Q Y Zheng; R S Smith; P M Nishina; J K Naggert
Journal:  Hum Mol Genet       Date:  2005-07-06       Impact factor: 6.150

Review 4.  Alström syndrome: insights into the pathogenesis of metabolic disorders.

Authors:  Dorothée Girard; Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-12-07       Impact factor: 43.330

5.  Pediatric myocarditis: A sentinel of non-cardiac chronic diseases?

Authors:  Gábor Mogyorósy; Enikő Felszeghy; Tamás Kovács; Andrea Berkes; László Tóth; György Balla; Ilma Korponay-Szabó
Journal:  Interv Med Appl Sci       Date:  2014-12-22

6.  Spectral-domain optical coherence tomography findings in Alström syndrome.

Authors:  Gad Dotan; Vikas Khetan; Jan D Marshall; Elizabeth Affel; Denise Armiger-George; Jürgen K Naggert; Gayle B Collin; Alex V Levin
Journal:  Ophthalmic Genet       Date:  2017-01-23       Impact factor: 1.803

7.  Alström syndrome: cardiac magnetic resonance findings.

Authors:  Francesco Corbetti; Renato Razzolini; Vera Bettini; Jan D Marshall; Jürgen Naggert; Francesco Tona; Gabriella Milan; Pietro Maffei
Journal:  Int J Cardiol       Date:  2012-04-10       Impact factor: 4.164

8.  Metabolic Syndrome in Childhood: Rare Case of Alstrom Syndrome with Blindness.

Authors:  Afzal Ahmad; Benedicta D'Souza; Charu Yadav; Ashish Agarwal; Anand Kumar; M Nandini; Vivian D'Souza; A M Poornima; Nutan Kamath
Journal:  Indian J Clin Biochem       Date:  2015-12-28

9.  Metabolic syndrome features presenting in early childhood in Alström syndrome: a case report.

Authors:  Özgür Pirgon; Mehmet Emre Atabek; Ilhan Asya Tanju
Journal:  J Clin Res Pediatr Endocrinol       Date:  2009-11-06

10.  Alström syndrome: genetics and clinical overview.

Authors:  Jan D Marshall; Pietro Maffei; Gayle B Collin; Jürgen K Naggert
Journal:  Curr Genomics       Date:  2011-05       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.